Postoperative Radiation Therapy for Non-Small Cell Lung Cancer and Thymic Malignancies
AbstractFor many thoracic malignancies, surgery, when feasible, is the preferred upfront modality for local control. However, adjuvant radiation plays an important role in minimizing the risk of locoregional recurrence. Tumors in the thoracic category include certain subgroups of non-small cell lung cancer (NSCLC) as well as thymic malignancies. The indications, radiation doses, and treatment fields vary amongst subtypes of thoracic tumors, as does the level of data supporting the use of radiation. For example, in the setting of NSCLC, postoperative radiation is typically reserved for close/positive margins or N2/N3 disease, although such diseases as superior sulcus tumors present unique cases in which the role of neoadjuvant vs. adjuvant treatment is still being elucidated. In contrast, for thymic malignancies, postoperative radiation therapy is often used for initially resected Masaoka stage III or higher disease, with its use for stage II disease remaining controversial. This review provides an overview of postoperative radiation therapy for thoracic tumors, with a separate focus on superior sulcus tumors and thymoma, including a discussion of acceptable radiation approaches and an assessment of the current controversies involved in its use. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Gomez, D.R.; Komaki, R. Postoperative Radiation Therapy for Non-Small Cell Lung Cancer and Thymic Malignancies. Cancers 2012, 4, 307-322.
Gomez DR, Komaki R. Postoperative Radiation Therapy for Non-Small Cell Lung Cancer and Thymic Malignancies. Cancers. 2012; 4(1):307-322.Chicago/Turabian Style
Gomez, Daniel R.; Komaki, Ritsuko. 2012. "Postoperative Radiation Therapy for Non-Small Cell Lung Cancer and Thymic Malignancies." Cancers 4, no. 1: 307-322.